1. Home
  2. LIXT vs STKH Comparison

LIXT vs STKH Comparison

Compare LIXT & STKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • STKH
  • Stock Information
  • Founded
  • LIXT 2005
  • STKH 2018
  • Country
  • LIXT United States
  • STKH Israel
  • Employees
  • LIXT N/A
  • STKH N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • STKH Packaged Foods
  • Sector
  • LIXT Health Care
  • STKH Consumer Staples
  • Exchange
  • LIXT Nasdaq
  • STKH Nasdaq
  • Market Cap
  • LIXT 12.4M
  • STKH 1.9M
  • IPO Year
  • LIXT N/A
  • STKH 2021
  • Fundamental
  • Price
  • LIXT $3.41
  • STKH $0.56
  • Analyst Decision
  • LIXT
  • STKH
  • Analyst Count
  • LIXT 0
  • STKH 0
  • Target Price
  • LIXT N/A
  • STKH N/A
  • AVG Volume (30 Days)
  • LIXT 136.6K
  • STKH 733.4K
  • Earning Date
  • LIXT 08-07-2025
  • STKH 09-02-2025
  • Dividend Yield
  • LIXT N/A
  • STKH N/A
  • EPS Growth
  • LIXT N/A
  • STKH N/A
  • EPS
  • LIXT N/A
  • STKH N/A
  • Revenue
  • LIXT N/A
  • STKH $10,000.00
  • Revenue This Year
  • LIXT N/A
  • STKH N/A
  • Revenue Next Year
  • LIXT N/A
  • STKH N/A
  • P/E Ratio
  • LIXT N/A
  • STKH N/A
  • Revenue Growth
  • LIXT N/A
  • STKH N/A
  • 52 Week Low
  • LIXT $0.64
  • STKH $0.48
  • 52 Week High
  • LIXT $5.14
  • STKH $17.20
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 44.33
  • STKH 26.34
  • Support Level
  • LIXT $3.13
  • STKH $0.48
  • Resistance Level
  • LIXT $4.04
  • STKH $0.88
  • Average True Range (ATR)
  • LIXT 0.57
  • STKH 0.09
  • MACD
  • LIXT -0.22
  • STKH 0.01
  • Stochastic Oscillator
  • LIXT 16.66
  • STKH 17.68

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About STKH Steakholder Foods Ltd.

Steakholder Foods Ltd is engaged in transforming the alternative protein industries through its technology. The group specializes in developing and selling 3D-printing production machines, supported by proprietary premix blends, formulated from the highest-quality raw ingredients. These tools help manufacturers of all sizes efficiently produce foods that meet consumer expectations for taste, texture, and appearance and offer a safe and sustainable alternative to industrialized meat and seafood production. The company's expertise in creating alternative protein products replicating traditional meats' complex textures such as beef steaks, white fish, shrimp, and eel. It also explores the integration of cultivated cells, preparing for future advancements in food technology.

Share on Social Networks: